Then we combined orlistat with sorafenib to treat HCC cells, and studied how FASN inhibition affects sorafenib-resistant HCC cells from cell cycle distribution, protein expressions, and glucose uptake. The gene discussed is FASN; the disease is hepatocellular carcinoma.